Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELPIS: Omission of surgery in HER2+ breast cancer
NCT04301375Phase 2Not yet recruiting
- Start
- Jun 2020
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab + pertuzumab in breast cancer. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
trastuzumab + pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04301375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301375.